Edmonton, Alberta, Canada/April 10, 2023- Pacylex Pharmaceuticals today announced it will be presenting at two exclusive life science startup events in Canada in April, spotlighting its emergence as one of the premier Canadian biotech startup companies. Pacylex is focused on innovative research and development and is a leader in the maturing Canadian biotech ecosystem.
A panel of pharmaceutical industry professionals selected Pacylex as one of only 16 Canadian startup companies to highlight at the annual Sweet Biopharma Day on April 12 in Mirabel, Québec. The following week, Pacylex will present at another invitation-only event, the Creative Destruction Labs (CDL)-Vancouver's Alumni Showcase on April 19. Pacylex was part of the CDL’s Health cohort in 2020 that was cut short by the COVID-19 pandemic.
At these events, CEO Michael Weickert will present the company’s progress and plans, highlighting clinical results and the potential of PCLX-001, a first-in-class, oral NMT inhibitor being developed by the company. The company’s Founder and CSO, Luc Berthiaume, will also attend the Sweet Biopharma Day. In between these events, advances in discovery research regarding NMT inhibition will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.
Participants at the Sweet Biopharma Day and CDL Alumni events include stakeholders from key global pharma and biopharma companies, support organizations, venture capitalists, and representatives from governments and associations. “We are honored to be offered the opportunity to participate at these events featuring the best of the emerging biotech companies in Canada,” said Michael Weickert, CEO of Pacylex. “As a member of BIOTECanada, we believe the Canadian biotech ecosystem is an economic strength that positions Canada well to successfully deliver innovation to a world looking for solutions, and we want to showcase how science at Pacylex is being translated into first-in-class products with the potential to dramatically impact patient care.”
About Pacylex Pharmaceuticals
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a first-in-class, oral, once daily therapeutic, PCLX-001. Pacylex has a US Subsidiary in the San Francisco Bay area. PCLX-001 is the lead drug in a new class of N-myristoyltransferase (NMT) inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1 multiple ascending dose study in Canada in patients with Diffuse Large B Cell Lymphoma (DLBCL) and solid tumors, and a Phase 2a dose expansion in patients with Non Hodgkin Lymphoma (NHL) is planned to start in Q2 2023 (ClinicalTrials.gov Identifier: NCT04836195). A Phase 1/2a clinical study in patients with Acute Myeloid Leukemia (AML) is also planned to start in Q2 2023. The US Department of Defense is supporting the initial clinical investigation of PCLX-001 in patients with AML. The FDA has granted PCLX-001 both Orphan Drug Designation and Fast Track Designation for AML. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. For additional information, please visit www.pacylex.com.
